financetom
Business
financetom
/
Business
/
EchoStar Q3 Loss Widens, Revenue Falls; Shares Down
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
EchoStar Q3 Loss Widens, Revenue Falls; Shares Down
Nov 6, 2025 4:03 AM

06:31 AM EST, 11/06/2025 (MT Newswires) -- EchoStar ( SATS ) reported Q3 loss Thursday of $44.37 per diluted share, widening from $0.52 a year earlier.

Three analysts surveyed by FactSet expected loss of $1.21. EchoStar ( SATS ) reported impairments in the quarter of $16.5 billion, as it began abandoning and decommissioning parts of its 5G network, according to a filing.

Revenue for the quarter ended Sept. 30 was $3.61 billion, down from $3.89 billion a year earlier. Analysts surveyed by FactSet expected $3.73 billion.

EchoStar ( SATS ) shares were up more than 3% in recent premarket activity.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
EnLink Midstream to Launch Senior Notes Offering
EnLink Midstream to Launch Senior Notes Offering
Aug 12, 2024
09:25 AM EDT, 08/12/2024 (MT Newswires) -- EnLink Midstream ( ENLC ) said Monday that it plans to launch an offering of senior notes. The midstream energy company said it plans to use the net proceeds to repay borrowings under its revolving credit facility, as well as an accounts receivable securitization facility. EnLink said the offering will be fully guaranteed...
Wave Life Sciences' Duchenne MD Treatment Candidate Gets US FDA Rare Pediatric Disease Designation
Wave Life Sciences' Duchenne MD Treatment Candidate Gets US FDA Rare Pediatric Disease Designation
Aug 12, 2024
09:26 AM EDT, 08/12/2024 (MT Newswires) -- Wave Life Sciences ( WVE ) said Monday the US Food and Drug Administration has given rare pediatric disease designation to its drug candidate WVE-N531 to treat boys with Duchenne muscular dystrophy who are amenable to exon 53 skipping. The drug is being assessed in a trial that enrolled 11 boys with the...
Ballard Power Down 2.5% In US Premarket As Posts Q2 Miss; Cites Decreases In Order Book; Cuts Its 2024 Capital Expenditure Guidance
Ballard Power Down 2.5% In US Premarket As Posts Q2 Miss; Cites Decreases In Order Book; Cuts Its 2024 Capital Expenditure Guidance
Aug 12, 2024
09:26 AM EDT, 08/12/2024 (MT Newswires) -- Ballard Power Systems ( BLDP ) , which delivers fuel cell power, was at last look down 2.5% in US premarket trade and near 52 week lows on Monday after it reported a wider second quarter loss on lower than expected revenues, and also cited decreases in its order book and cut its...
ImmunityBio Says Anktiva Now Available Under US Commercial, Government Insurance Plans
ImmunityBio Says Anktiva Now Available Under US Commercial, Government Insurance Plans
Aug 12, 2024
09:25 AM EDT, 08/12/2024 (MT Newswires) -- ImmunityBio ( IBRX ) said Monday that Anktiva is now available for patients under both commercial and government insurance plans in the US. The US Food and Drug Administration approved Anktiva, the company's immunotherapy to treat Bacillus Calmette-Guerin-unresponsive non-muscle invasive bladder cancer, in April. Additionally, ImmunityBio ( IBRX ) has started the filing...
Copyright 2023-2026 - www.financetom.com All Rights Reserved